Recent developments in systemic chemotherapy for hepatocellular carcinoma / 대한간학회지
The Korean Journal of Hepatology
;
: 4-11, 2008.
Article
in Korean
| WPRIM
| ID: wpr-160194
ABSTRACT
Despite recent developments in various chemotherapeutic agents and the performing of numerous clinical trials, chemotherapy still produces unsatisfactory results in hepatocellular carcinoma due to poor clinical benefit compared with untreated controls and its significant toxicity. The presence of liver cirrhosis, its complications, and decreased liver function increase the complexity of chemotherapy. There is recent evidence that targeted agents and antiangiogenic agents such as thalidomide are somewhat effective whilst having minimal toxicities. Some patients are cured by aggressive chemotherapy alone or in combination with other modalities. Therefore, if a patient is in good condition and the tumor shows some response to chemotherapy, aggressive chemotherapy might be considered. Although conventional chemotherapeutic agents are not very effective in many patients, their utility might be improved by lowering toxicities using reduced doses or by selecting only responsive patients if adequate chemosensitivity tests are available. Imaging studies have been conventional tools for evaluating tumor responses, but their results are not always reliable. Establishing criteria for accurately determining tumor responses is urgently needed, along with better chemotherapeutic drugs and regimens.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Tegafur
/
Combined Modality Therapy
/
Carcinoma, Hepatocellular
/
Antineoplastic Agents, Hormonal
/
Deoxycytidine
/
Fluorouracil
/
Immunologic Factors
/
Liver Neoplasms
/
Antibodies, Monoclonal
/
Antimetabolites, Antineoplastic
Limits:
Humans
Language:
Korean
Journal:
The Korean Journal of Hepatology
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS